Earnings summaries and quarterly performance for bioAffinity Technologies.
Executive leadership at bioAffinity Technologies.
Board of directors at bioAffinity Technologies.
Research analysts who have asked questions during bioAffinity Technologies earnings calls.
Recent press releases and 8-K filings for BIAF.
bioAffinity Technologies Reports Q3 2025 Financial Results
BIAF
Earnings
Revenue Acceleration/Inflection
Board Change
- bioAffinity Technologies reported a net loss of $5.1 million for the third quarter of 2025, compared to a net loss of $2.0 million for the same period in 2024, primarily due to an expense recorded for the change in fair value of warrants issued.
- Total revenue for Q3 2025 was $1.5 million, a decrease from $2.4 million in Q3 2024, attributed to the strategic decision to discontinue unprofitable pathology services. However, CyPath® Lung testing revenue increased approximately 122% year over year for Q3 2025, with sales reaching a record high, representing a 92% increase over the previous quarter.
- The company strengthened its balance sheet by raising approximately $10.4 million in gross proceeds from equity transactions in Q3 2025, resulting in cash and cash equivalents of $7.7 million as of September 30, 2025, up from $1.1 million at December 31, 2024.
- Key operational highlights include regaining full Nasdaq Capital Market compliance and appointing Roberto Rios, CPA, and John J. Oppenheimer, M.D., to the Board of Directors.
Nov 14, 2025, 1:30 PM
bioAffinity Technologies Reports Significant Growth in CyPath® Lung Test Volume
BIAF
Revenue Acceleration/Inflection
- bioAffinity Technologies, Inc. announced accelerating month-over-month growth in its CyPath® Lung test volume.
- In October 2025, test volume increased by 111% over the 2025 year-to-date monthly average.
- The number of CyPath® Lung tests processed has more than doubled since the start of 2025, with third-quarter sales volume increasing 95% over the prior quarter.
- Medical practices with multiple CyPath® Lung orders increased 106% in the third quarter compared to the prior quarter.
Nov 5, 2025, 1:30 PM
bioAffinity Technologies announces U.S. patent allowance for lung cancer diagnostic algorithm
BIAF
New Projects/Investments
- bioAffinity Technologies, Inc. announced on October 16, 2025, that it received a notification of allowance from the United States Patent and Trademark Office (USPTO) for a new patent.
- The patent covers an AI-built algorithm and flow cytometry platform used in the company's CyPath® Lung test for detecting early-stage lung cancer.
- This allowance expands bioAffinity's global patent estate to 18 awarded and 33 pending patents.
Oct 16, 2025, 1:15 PM
bioAffinity Technologies Regains Nasdaq Listing Compliance
BIAF
Delisting/Listing Issues
- bioAffinity Technologies, Inc. (BIAF) announced on October 15, 2025, that it has regained compliance with all Nasdaq continued listing requirements.
- The company now meets the Nasdaq Listing Rule 5550(a)(2) for a minimum closing bid price of $1.00 per share and Nasdaq Listing Rule 5550(b)(1) for a minimum of $2.5 million in stockholders' equity.
- As a result, bioAffinity Technologies' common stock (BIAF) and warrants (BIAFW) will continue to trade on the Nasdaq Capital Market.
- Nasdaq has imposed a one-year Mandatory Panel Monitor, during which any failure to comply with the Equity Rule will not grant additional time to regain compliance, though a new hearing can be requested before delisting.
Oct 15, 2025, 1:15 PM
bioAffinity Technologies Announces Closing of $1.8 Million Registered Direct Offering
BIAF
- bioAffinity Technologies, Inc. announced the closing of a registered direct offering on October 9, 2025, raising approximately $1.8 million in gross proceeds.
- The offering involved the sale of 720,000 shares of common stock at a price of $2.50 per share.
- The company plans to use the net proceeds for working capital, to support sales of its noninvasive lung cancer test CyPath® Lung, and for general corporate purposes.
- As part of the agreement, bioAffinity Technologies will not issue common stock or equivalents until November 14, 2025, and its officers and directors are subject to 60-day lock-up agreements from the closing date.
Oct 9, 2025, 9:04 PM
bioAffinity Technologies Closes $1.8M Registered Direct Offering
BIAF
New Projects/Investments
- bioAffinity Technologies closed a previously announced registered direct offering of 720,000 shares of common stock at a purchase price of $2.50 per share.
- The offering was priced at-the-market under Nasdaq rules.
- The company intends to use the net proceeds for working capital, to support expected growing sales for CyPath® Lung, and for general corporate purposes.
- WallachBeth Capital LLC acted as the sole placement agent for the offering.
Oct 9, 2025, 6:00 PM
bioAffinity Technologies Reports Record CyPath® Lung Test Volume in Q3 2025
BIAF
Revenue Acceleration/Inflection
New Projects/Investments
- bioAffinity Technologies, Inc. announced that sales of its CyPath® Lung diagnostic test for lung cancer reached a new high in the third quarter of 2025.
- This record volume represents a 95% increase over the previous quarter and a 97% rise in sales for the first nine months of 2025 compared to the same period in 2024.
- The growth is attributed to increased adoption by Veterans’ hospitals and market expansion in the mid-Atlantic region, alongside a 77% increase in new patients and improved patient compliance for at-home sample collection in Q3 2025.
Oct 7, 2025, 9:16 PM
bioAffinity Technologies Closes $4.8 Million Public Offering
BIAF
Delisting/Listing Issues
- bioAffinity Technologies announced the closing of a public offering on September 30, 2025, generating aggregate gross proceeds of $4.8 million.
- The offering consisted of 1,921,761 shares of Common Stock (or pre-funded warrants) at a purchase price of $2.50 per share (or $2.493 per Pre-Funded Warrant).
- As of September 30, 2025, after the closing of this offering and the exercise of certain Pre-Funded Warrants, there are 3,100,402 shares of Common Stock outstanding.
- The company believes it has regained compliance with Nasdaq's Continued Listing Equity Requirement, with stockholders' equity exceeding $2,500,000, partly due to this offering and a 1-for-30 reverse stock split that became effective on September 18, 2025.
Sep 30, 2025, 9:05 PM
bioAffinity Technologies Closes Public Offering
BIAF
- bioAffinity Technologies, Inc. closed a public offering of securities, generating $4.8 million in aggregate gross proceeds before deducting agent fees and other estimated expenses.
- The offering consisted of 1,921,761 shares of Common Stock (or pre-funded warrants) at a purchase price of $2.50 per share (or $2.493 per Pre-Funded Warrant).
- WallachBeth Capital LLC served as the sole placement agent for the offering.
Sep 30, 2025, 4:44 PM
bioAffinity Technologies Announces 1-for-30 Reverse Stock Split
BIAF
Delisting/Listing Issues
- bioAffinity Technologies, Inc. (BIAF) announced a 1-for-30 reverse stock split of its common stock.
- The reverse stock split will become effective on September 18, 2025, at 4:01 p.m. Eastern Time, with trading on a split-adjusted basis commencing on September 19, 2025 on the Nasdaq Capital Market.
- The primary purpose of the reverse stock split is to comply with Nasdaq's minimum bid price requirement.
- Following the split, the company will have approximately 1,338,029 shares of common stock issued and outstanding, and stockholders will receive cash in lieu of fractional shares.
Sep 17, 2025, 8:30 PM
Quarterly earnings call transcripts for bioAffinity Technologies.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more